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Abstract
Staphylococcus aureus is a bacterial pathogen that is distributed worldwide and represents an increasing problem, both in hospitals and in the
community. Global transmission of methicillin-resistant S. aureus (MRSA) has been the subject of many studies. Determining the incidence of
colonization with community-acquired MRSA in hospitalized patients and outpatients has been the aim of several studies conducted in the
Middle East (western Asia). The local epidemiology within countries in this region is changing, owing to the introduction of new strains with
the intercontinental exchange of several clones. Sequence type 80-MRSA-IV is one common clone detected in different countries within the
region showing country-based differences, and hence more likely to form clonal lineages. MRSA is endemic in this region, and the burden
and the difficulty in detecting imported strains are increasing. This is also increasing the risk of domestic and global transmission. To counter
the threat associated with the high incidence of MRSA carriage and infections, systematic surveillance of both hospital and community
isolates is required, along with appropriate measures designed to limit their spread. Additionally, antibiotic stewardship is needed to contain
the further development of the observed resistance and to help in preserving antibiotics as precious therapeutic resources. It is critical for
countries in this region to establish both national and international initiatives to develop better measurements designed to limit and control
the spread of infections. Finally, more sequence-based studies are needed to better understand the pathogenicity and epidemiology of these
important pathogens.
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Introduction
Staphylococcus aureus is a major human pathogen that causes a
broad range of serious community-acquired and nosocomial
diseases in humans, from minor skin infections to severe
infections such as septicaemia [1]. The increasing prevalence of
methicillin-resistant S. aureus (MRSA) and its ability to spread
in hospitals and the community have posed a major challenge
for infection control [2].
Since the introduction of methicillin for the treatment of
penicillin-resistant Staphylococcus strains in 1959, MRSA has
emerged as an important hospital-associated pathogen,
because of increased morbidity and mortality rates, healthcare
costs, and length of hospital stays [3,4]. Hospital-associated
MSRA (HA-MRSA) infections arise in individuals with
predisposing risk factors, such as surgery or the presence of
an indwelling medical device. In contrast, many commu-
nity-acquired MRSA (CA-MRSA) infections arise in otherwise
healthy individuals who do not have such risk factors, and are
known to be epidemic in some countries [5,6]. These features
suggest that CA-MRSA are more virulent and transmissible
than are traditional HA-MRSA [5,6].
The epidemiology of MRSA varies considerably on a global
basis, and the spread of several CA-MRSA clones and their
dissemination into hospitals have made understanding the
epidemiology more difficult [1]. CA-MRSA lineages are geno-
typically and phenotypically unrelated to multidrug-resistant
HA-MRSA, and have recently started to replace the once
pandemic HA-MRSA clones (clonal complex (CC)5, CC8,
CC22, CC36, and CC45) in healthcare facilities [7,8].
CA-MRSA infections have been dominated by five lineages:
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sequence type (ST)1-IV (USA400), ST8-IV (USA300), ST30-IV
(Pacific/Oceania; South West Pacific clone), ST59-IV/V
(USA1000, Taiwan), and ST80-IV (European CA-MRSA), each
being geographically restricted [6]. However, these originally
continent-specific clones have spread to other parts of the
world; ST1 clone USA400, for example, has been detected in
Europe and Asia. Some Panton–Valentine leukocidin (PVL)-
positive clones, such as ST1 and ST30, are pandemic, having
been detected in America, Europe, and Asia [5]. ST80, known
as the European clone, has also been reported in Libya, Jordan,
and Lebanon [9,10].
Global transmission of MRSA linked to international travel
has been the subject of many studies [9–11]. However, in
countries with a high prevalence of MRSA, imported cases of
MRSA are not easily distinguished from the domestic back-
ground prevalence. Information about the epidemiology of
MRSA in non-European countries of the south-eastern Med-
iterranean has been sparse. Borg et al. [11] collected the
largest dataset on the epidemiology of MRSA in this region,
and showed the significant presence of MRSA in this part of
the world, with many hospitals showing evidence of endemic-
ity. It is worth noting that healthcare in such countries is more
concentrated in urban areas. The reported catchment popu-
lations can therefore be underestimated, as it is difficult to
estimate the proportion of the population coming from the
rural areas to a particular hospital in the city [11].
The purpose of this review is to summarize what has
recently been reported about the epidemiology of CA-MRSA
in the Middle East, specifically covering western Asia, and
touch upon the clinical spectrum of infectious syndromes
associated along with resistance patterns.
Epidemiology of MRSA in the Middle East
The incidence of patient colonization with CA-MRSA has been
the aim of several studies conducted in the region. Epidemiolog-
ical data on CA-MRSA carriage and infection in the Middle East
are limited; there is no information on the MRSA population
structure, and little attention has been paid to the molecular
epidemiology of this pathogen. CA-MRSA infections have
changed markedly, and are expanding to also become causative
agents of nosocomial infections. Recently, several studies have
reported on MRSA carriage and/or infection coming from
different countries in the south-eastern Mediterranean region.
Palestine
A study conducted throughout the Gaza strip by Biber et al.
[12] revealed widespread CA-MRSA carriage, whereby 30% of
healthy children and their parents carried S. aureus. Nine-
ty-four MRSA were identified, and further molecular charac-
terization revealed the predominance of CC22, which included
70 strains. The SCCmec type of the Gaza strain was IVa,
whereas nine pulsed-field gel electrophoresis-related isolates
carried SCCmec V, and seven of these belonged to ST22.
Interestingly, eight of the 94 MRSA were PVL-positive and
belonged to ST80-MRSA-IV. The authors hypothesized that
the origin of the Gaza clone was either an HA-MRSA that
spread in the community, or a local ST22-methicillin-sensitive
S. aureus (MSSA) that evolved into a novel CA-MRSA clone. In
a study conducted to determine the carriage rate and
characteristics of CA-MRSA in patients admitted to Ramallah
Governmental Hospital, a total of 843 swabs were obtained
from patients who had no contact with healthcare workers at
the time of hospital admission. For comparison purposes, the
study also included samples collected from 72 volunteer
healthcare workers working in close contact with patients in
the internal medicine wards. The study revealed that the rate
of S. aureus colonization at the time of admission was 26%, and
that the rate of MRSA carriage was 2% [13]. Among the
healthcare workers, S. aureus was detected in 21% and MRSA
in 14%. Sabri et al. [14] also attempted to study the molecular
epidemiology of MRSA circulating in Palestine, Jordan, and Iraq.
Investigation of the genetic association between 12 represen-
tative MRSA from the predominant antibiotic resistance
pattern revealed that 11 of these isolates shared a common
spa type (t932) and were SCCmec type III. Few of the isolates
were PVL-positive, being mainly hospital-acquired. This
regional clustering was attributed to cross-border patient
mobility. Finally, the prevalence of nasal carriage of S. aureus
and MRSA was investigated among 360 healthy university
students at An-Najah National University, Palestine [15]. The
study also included 46 clinical MRSA obtained from three
different health centres in northern Palestine within the same
period of the study. Nasal carriage of S. aureus was detected in
24% of the students with MRSA, accounting for 9% of the
isolates. Almost half of the MRSA belonged to SCCmec
types IVa and V, and the other half belonged to SCCmec
types II and III. SCCmec type IVa was found to be circulating
among nasal carriers both in students and in healthcare
workers.
Jordan
The incidence of colonization with CA-MRSA has also been
the subject of several studies conducted in Jordan. Daghistani
et al. [16] showed that 22.7% of nasal specimens collected
from 132 healthy students were positive for S. aureus. The
study included 80 S. aureus recovered randomly from wound
specimens, and showed that toxic shock syndrome toxin-1
production was higher among the nasal isolates. More recently,
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among 860 nasal and stool specimens collected from 430
infants admitted to the neonatal intensive-care unit or referred
to the outpatient clinics of Jordan University Hospital, 12.4% of
the samples were positive for S. aureus [17]. The incidence of
MRSA was 53%; 28% of the isolates were PVL-positive, and
they were mainly recovered from outpatients. All PVL-positive
isolates carried SCCmec IV, except for one with SCCmec
type III. On another note, a study of the prevalence of natural
carriage and molecular epidemiology of MRSA in a Jordanian
community revealed that the MRSA carriage rate in 227
healthy volunteers was 7.5%, with the majority of isolates
(81%) harbouring SCCmec IVe and being of the novel spa type
t9519 (76%) [18]. Other detected spa types were t233 (14.7%)
and t044 (5.9%). Moreover, Khalil et al. [9] performed
molecular characterization of 103 S. aureus (41 MRSA and 62
MSSA) recovered from stool and nose specimens collected
from children admitted to the Jordan university hospital.
Genotyping revealed 48 different spa types and identified
distinct allelic profiles, with the majority belonging to ST80.
Eight different pulsotypes were detected; SCCmec IV was seen
in 53% of the isolates, and clustering revealed that
ST80-MRSA-IV was the dominant type.
Lebanon
The situation in Lebanon is similar to that in Jordan and
Palestine, with limited data being available on S. aureus
colonization and its prevalence in patients. Sfeir et al. [19]
conducted a study to evaluate the rate of S. aureus nasopha-
ryngeal colonization in a population of individuals in an
outpatient department in Beirut, and to correlate this with
the impact of several possible risk factors. Of 1526 outpatients
tested, 133 (8.7%) carried S. aureus in the nose and/or throat,
with only two cases being MRSA. Risk factors for S. aureus
colonization included the following: a relative working in
healthcare, the presence of an intravascular device, a recent
dental procedure, and health club use. Nonetheless, molecular
characterization of 130 S. aureus (93 MRSA and 37 MSSA)
recovered from patients at the Clinical Microbiology Section of
the American University of Beirut in Lebanon revealed the
presence of 48 spa types that clustered into 30 different spa
CCs. Multilocus sequence typing revealed ten STs among the
isolates, and the majority of the PVL-positive isolates (53%)
were ST80-MRSA-IVc [20]. However, a similar, more recent,
study was conducted on 132 S. aureus non-duplicate clinical
isolates recovered in a period of 6 months at the Clinical
Microbiology Section of the American University of Beirut
[10]. The proportion of MRSA collected in this study was 30%,
which was significantly lower than the percentage reported
previously (72%) by Tokajian et al. [20]. This was attributed to
the fact that the study by Tokajian et al. [20] was based on a
number of randomly collected isolates. SCCmec typing again
showed the prevalence of the mobile genetic element SCCmec
type IV (85%), with all of the isolates being positive for the PVL
gene. Higher diversity was detected than that reported
previously [20]; 71 different spa types as compared with 48.
The most common were: t021 (6%), t044 (5%), and t267 (5%).
Clustering of SCCmec types with multilocus sequence types
identified seven MRSA and 20 MSSA clones, and confirmed
that the PVL-positive ST80-MRSA-IV was the dominant clone
in Lebanon, followed by PVL-positive ST30-MSSA (5%) [10].
Egypt and Algeria
A randomized study in Egypt on healthcare workers in
different hospital departments was conducted to test for the
effect of linezolid on nasal and throat colonization [21]. A total
of 134 healthcare workers were screened, and 43 (32%) were
found to be MRSA carriers (41 nasal carriers and two nasal
plus throat carriers). The study concluded that linezolid was
effective in eradicating both nasal and nasal plus throat
colonization. However, a study of the prevalence of PVL in
CA-MRSA isolated in Egypt showed that the prevalence of
PVL-positive MRSA was 19% [22]. These belonged to different
genetic clones, with the multilocus sequence types being ST30,
ST80, and a novel type, ST1010. Interestingly, however, the
Egyptian ST80 was different from the CA-MRSA ST80 isolated
from other countries. The Egyptian ST80 contained the etd and
pvl genes and carried SCCmec IV, but had a different spa type
(983/t042) and a unique antimicrobial resistance pattern, i.e.
no resistance to tetracycline and fusidic acid, but resistance to
sulphamethoxazole [22].
In Algiers, 24 of 25 MRSA implicated in infections of
neonates and children admitted to a hospital during an
18-month period carried SCCmec type IVc and belonged to
ST80, with 22 carrying the pvl gene. The study concluded that
PVL-positive ST80-MRSA-IVc was the dominant MRSA clone
causing disease in neonates and children [23].
Resistance Patterns
Different antibiotic regimens between countries in this region
possibly contributed to the development of heterogeneous
strains. An investigation of the prevalence of nasal carriage of
MRSA at An-Najah National University in Palestine, and a
comparison with clinical isolates, revealed that 35% were
multidrug-resistant, being resistant to b-lactams and two or
more of ciprofloxacin, erythromycin, and clindamycin [15].
MRSA (eight nasal and 46 clinical) had a broad range of
antibiotic resistance. Rates of resistance to non-b-lactam
antibiotics were also high: erythromycin, 96%; clindamycin,
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52%; and ciprofloxacin, 48% [15]. Sabri et al. [14]
reported similar high rates of resistance in clinical MRSA
to erythromycin, clindamycin, ciprofloxacin, gentamicin and
sulphamethoxazole–trimethoprim in the West Bank of
Palestine, Jordan, and Iraq. However, Kaibni et al. [13]
determined the carriage rate of CA-MRSA in Palestine in
samples collected from Ramallah Governmental Hospital
(patients and healthcare workers). The study, which was
based on 27 MRSA (17 from patients and ten from healthcare
workers), showed that the rates of resistance to non-b-lactam
antibiotics were 29.6% for ciprofloxacin, 18.5% for erythro-
mycin, 11.1% for clindamycin, and 7.4% for tetracycline. This
was in contrast to results obtained in Jordan by Al-Bakri et al.
[18], who also studied carriage rates in apparently healthy
volunteers, and reported that all MRSA were resistant to all
b-lactam antibiotics but susceptible to other tested agents. In
line with these results, Shehabi et al. [17], who also investi-
gated the colonization of hospitalized and outpatient infants
with S. aureus, found that almost 94% of PVL-positive MRSA
were susceptible to gentamicin, clindamycin, chloramphenicol,
and vancomycin.
In Lebanon, a study on S. aureus nasopharyngeal coloniza-
tion in outpatients revealed the continued effectiveness of
cephalosporins as first-line therapy for community-acquired
skin and soft tissue infections. Nonetheless, a study on
susceptibility patterns in clinical isolates collected from the
same country revealed that 56% were susceptible to all tested
antibiotics, with the rest being resistant to one or more of the
used antibiotics [9]. Finally, Kanj et al. [24] recently, and under
the Tigecycline Evaluation and Surveillance Trial, reported that
all S. aureus, including MRSA, were susceptible to tigecycline,
linezolid, and vancomycin.
Conclusion
In conclusion, MRSA has emerged as an important pathogen of
community infections in many countries in the Middle East.
With the global transmission of MRSA, the local epidemiology
within countries in the Middle East is changing, owing to the
introduction of new strains, with the intercontinental
exchange of several clones. ST80-MRSA-IV is one common
clone detected in different countries within the region, and is
more of a clonal lineage, with country-based differences being
detected. In Lebanon, most of the isolates belonging to this
clonal lineage were found to be related to the European
ST80-MRSA-IV clone [9,10,20,25], this was not the case
however, for the isolates from Jordan, which were distin-
guished particularly by being positive for the toxic shock
syndrome toxin-1 gene [9,10,17,18].
MRSA is endemic to the Mediterranean region [11], which
increases the burden and the difficulty in detecting imported
strains. This increases the risk of domestic transmission, in
light of patient and personnel movements, and global
transmission through travellers and immigrants. To counter
the threat associated with the high incidence of MRSA
carriage and infections in this region, systematic countrywide
surveillance of both hospital and community isolates is
required, along with appropriate measures designed to limit
their spread. Screening and decolonization of carriers has
been successful in containing some outbreaks of CA-MRSA,
and may lead to appropriate measures that would additionally
help to reduce the rate of MRSA infections. Additionally,
antibiotic stewardship has an important role in containing the
further development of the observed resistance in this
region, and in preserving antibiotics as precious therapeutic
resources.
One of the major additional difficulties encountered in these
countries is the lack of sourcing of relevant clinical and
demographic information, which explains the lack of accurate
incidence rates. A high degree of variation of MRSA has been
reported, which might be attributable both to the surge of
MRSA infections and, more importantly, to the fact that most
of the published interpretations were based on a few hospitals
in one city rather than being countrywide.
Hence, endemicity of MRSA is clearly a problem in the
region, and has major consequences for the countries
themselves, as well as for neighbouring nations. The ineffec-
tiveness of MRSA infection control and prevention is driving
regional dissemination. It is therefore critical for countries in
this region to improve systematic surveillance, and to establish
both national and international initiatives to develop better
measurements designed to limit and control the spread of
infections. Finally, more sequence-based studies are needed to
better understand the pathogenicity and epidemiology of these
important pathogens.
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